OS by treatment type, patient age, and transplant status. (A) OS from the time of treatment initiation for the entire cohort of patients with newly diagnosed NPM1-mutant AML aged ≥60 years by treatment type (intensive induction chemotherapy [IC; red] vs HMA/VEN [blue]). Because there were statistically significant differences in treatment assignment by age, we performed a (B) subgroup analysis restricted to patients aged 60 to 75 years . (C) OS for patients who underwent an allo-SCT by type of initial AML treatment.